Results 1 to 10 of about 100,230 (154)

Effect of tranexamic acid in the treatment of angiotensin-converting enzyme inhibitor-induced angioedema: A systematic review and meta-analysis [PDF]

Turkish Journal of Emergency Medicine
OBJECTIVE: To assess the effectiveness of tranexamic acid (TXA) in the treatment of angiotensin-converting enzyme inhibitor-induced angioedema. METHODS: A systematic review was conducted using PubMed, Scopus, Embase, and ProQuest databases from inception
Kanmani Indra Couppoussamy, Sasikumar Mahalingam, Gunaseelan Rajendran, Suruthi Purushothaman, Anitha Ramkumar, Yuvaraj Krishnamoorthy, Ezhilkugan Ganessane, Aswin Kumaran   +7 more
doaj   +2 more sources

Late-Onset Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema in a General Practitioner’s Practice: A Case Report [PDF]

Reports
Background and Clinical Significance: Angiotensin-converting enzyme inhibitors (ACE-Is) are commonly used for treatment of hypertension and are well known among primary care specialists. ACE-I-induced angioedema is a rare, yet possible side effect.
Eva Jūlija Tirāne, Edgars Tirāns
doaj   +2 more sources

Association between angiotensin-converting enzyme inhibitor-induced cough and the risk of lung cancer: a Mendelian randomization study [PDF]

Frontiers in Pharmacology, 2023
Background: Observational studies and meta-analyses have demonstrated a positive correlation between the use of angiotensin-converting enzyme inhibitors (ACEIs) and lung cancer.
Taikang Yao, Taikang Yao, Zhenchao Wu, Zilu Wang, Zilu Wang, Liting Chen, Liting Chen, Beibei Liu, Ming Lu, Ning Shen   +9 more
doaj   +2 more sources

Tranexamic acid for angiotensin-converting enzyme inhibitor–induced angioedema [PDF]

Clinical and Experimental Emergency Medicine
Approximately 0.7% of patients taking angiotensin-converting enzyme inhibitors (ACEIs) develop ACEI-induced angioedema (ACEI-IA). With no approved treatments for ACEI-IA, the risk of complications is concerning. Tranexamic acid (TXA) has the potential to
Gaurav Nitin Pathak, Thu Minh Truong, Abhishek Chakraborty, Babar Rao, Catherine Monteleone   +4 more
doaj   +2 more sources

Angiotensin-converting Enzyme Inhibitors: Can it be a Potential Treatment of Infantile Hemangioma

Journal of Indian Association of Pediatric Surgeons, 2021
Aims: The aim of the sudy was to evaluate potential role of oral captopril, an angiotensin-converting enzyme (ACE) inhibitor, and in treatment of infantile hemagioma (IH) and report our preliminary results.
Archika Gupta, Shiv Narain Kureel, Anand Pandey, Gurmeet Singh, Akhilesh Kumar, Gaurav Shandilya, Rahul Kumar Rai, Survesh Kumar Gupta   +7 more
doaj   +1 more source

Angiotensin-Converting Enzyme Inhibitors [PDF]

Circulation, 1998
Abstract—ACE inhibitors have achieved widespread usage in the treatment of cardiovascular and renal disease. ACE inhibitors alter the balance between the vasoconstrictive, salt-retentive, and hypertrophic properties of angiotensin II (Ang II) and the vasodilatory and natriuretic properties of bradykinin and alter the metabolism of a number of other ...
N J, Brown, D E, Vaughan
openaire   +2 more sources

Antecedent Administration of Angiotensin‐Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID‐19 Syndrome

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) utilizes the angiotensin‐converting enzyme‐2 (ACE‐2) receptor to enter human cells.
Alberto Palazzuoli, Massimo Mancone, Gaetano M. De Ferrari, Giovanni Forleo, Gioel G. Secco, Gaetano M. Ruocco, Fabrizio D'Ascenzo, Silvia Monticone, Anita Paggi, Marco Vicenzi, Anna G. Palazzo, Maurizio Landolina, Erika Taravelli, Guido Tavazzi, Francesco Blasi, Fabio Infusino, Francesco Fedele, Francesco G. De Rosa, Michael Emmett, Jeffrey M. Schussler, Kristen M. Tecson, Peter A. McCullough   +21 more
doaj   +1 more source

Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Renin‐angiotensin aldosterone system (RAAS) inhibitor—COVID‐19 studies, observational in design, appear to use biased methods that can distort the interaction between RAAS inhibitor use and COVID‐19 risk. This study assessed the extent of bias
Jordan Loader, Frances C. Taylor, Erik Lampa, Johan Sundström   +3 more
doaj   +1 more source

Incidence of angiotensin-converting enzyme inhibitor-induced cough in a Malaysian public primary care clinic: A retrospective cohort study [PDF]

Malaysian Family Physician, 2022
Introduction: The incidence of angiotensin-converting enzyme inhibitors (ACEi)-induced cough has been reported between 5% and 30% but is unknown in Malaysia.
Hou Chan Loo, Fairuz Osman, Siew Lee Ho, Sing Yee An, Yim Mei Au Yong, Ee Ming Khoo   +5 more
doaj   +1 more source

Could Anti‐Hypertensive Drug Therapy Affect the Clinical Prognosis of Hypertensive Patients With COVID‐19 Infection? Data From Centers of Southern Italy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
BACKGROUND Coronavirus disease 2019 (COVID‐19) is the cause of a pandemic disease, with severe acute respiratory syndrome by binding target epithelial lung cells through angiotensin‐converting enzyme 2 in humans.
Celestino Sardu, Paolo Maggi, Vincenzo Messina, Pasquale Iuliano, Antonio Sardu, Vincenzo Iovinella, Giuseppe Paolisso, Raffaele Marfella   +7 more
doaj   +1 more source